CEFUROXIME KRKA 250 mg, film-coated tablet 8 tablets
Active ingredients: Cefuroxime, Cefuroxime axetil
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet8 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CEFUROXIME KRKA 250 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyyamide orienté aluminium PVC de 8 comprimé(s)
- Marketing authorisation holder
- KRKA (SLOVENIE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Dec 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65399255CIP73004190CIP133400930041901Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CÉFUROXIME AXÉTILcomprimé | 300,715 mg · un comprimé | SA |
| CÉFUROXIMEcomprimé | 250 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.